Prediction: Moderna Stock Will Soar 100% by 2030

Published September 30, 2026 · Category: Finance

Overview

Moderna (NASDAQ: MRNA) delivered an enormous win for investors during the early days of the pandemic thanks to its leadership in the coronavirus vaccine market. But when demand for the vaccine, at the time the biotech's only commercialized product, declined, so did the company's earnings. And the stock followed, spending a few years in the doldrums.

But in recent times, Moderna has made a turnaround. The company's cost realignment plan is bearing fruit, and pipeline candidates are progressing toward the finish line. Investors were particularly impressed with data from a late-stage trial of Moderna's personalized cancer vaccine. Meanwhile, Moderna has also won approval for new products, the most recent being an mRNA flu vaccine, launching for the current season. The biotech even predicts that revenue this year may advance as much as 10%.

Details

Considering all of this, my prediction is that Moderna stock will soar 100% by 2030. Let's consider the case.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Crude oil exports through the Strait of Hormuz hit prewar levels, but fuel shipments remain constrained
• Watch CNBC's full interview with Citadel's Ken Griffin and Carnegie Mellon University President Farnam Jahanian
• A Centuri Holdings Director Buys Over 5,000 Shares Near the Stock's One-Year Low